What is the appropriate treatment for urticaria (hives) and contact dermatitis?

Treatment of Urticaria (Hives) and Contact Dermatitis

For urticaria, start with standard-dose second-generation H1-antihistamines, escalate to 4-fold dosing if needed within 2-4 weeks, then add omalizumab 300mg every 4 weeks as second-line therapy for refractory cases. 1

For contact dermatitis, use mid-to-high potency topical corticosteroids (triamcinolone 0.1% or clobetasol 0.05%) for localized disease, and systemic corticosteroids tapered over 2-3 weeks for extensive involvement (>20% body surface area). 2, 3

Urticaria Treatment Algorithm

First-Line: Antihistamines

• Begin with standard-dose second-generation H1-antihistamines (e.g., cetirizine, loratadine, fexofenadine)
• If inadequate control after 2-4 weeks (or earlier if symptoms are intolerable), increase dose up to 4-fold 1
• Use the Urticaria Control Test (UCT) to assess disease control; a score <16 indicates inadequate control requiring escalation 1

Second-Line: Omalizumab

• Add omalizumab 300mg subcutaneously every 4 weeks to ongoing antihistamine therapy 1
• Allow up to 6 months for patients to respond to omalizumab
• For insufficient response, consider updosing by shortening intervals and/or increasing dosage
• Maximum recommended dose: 600mg every 2 weeks 1
• Higher doses particularly benefit patients with high body mass index 1

Third-Line: Cyclosporine

• Reserve for patients who fail higher-than-standard doses of omalizumab 1
• Dose: up to 5mg/kg body weight 1
• Monitor blood pressure and renal function (BUN, creatinine) every 6 weeks due to risks of hypertension, renal failure, hirsutism, and gum hypertrophy 1

Step-Down Strategy

• Once complete control is achieved (UCT ≥16), consider stepping down treatment
• For updosed antihistamines: maintain complete control for at least 3 consecutive months before reducing
• Reduce by no more than 1 tablet per month 1
• If breakthrough symptoms occur, return to the last effective dose 1

Role of Systemic Corticosteroids in Urticaria

While commonly used, systemic corticosteroids have limited evidence in urticaria. They likely improve urticaria activity by 14-15% absolute difference in patients with low-to-moderate antihistamine responsiveness (NNT=7), but only 2.2% in high responders (NNT=45). Importantly, they increase adverse events by 15% (NNH=9) 4. Use short courses only for acute flares when symptoms are intolerable, not as routine therapy.

Topical corticosteroids have minimal role in urticaria—they may reduce wheal size but show uncertain benefit for itch and should not be primary therapy 5.

Contact Dermatitis Treatment Algorithm

Diagnosis First

• Offer patch testing with baseline allergen series to all patients with suspected contact dermatitis 2
• Clinical features alone cannot distinguish allergic from irritant or endogenous dermatitis, particularly on hands and face 2
• Consider additional allergen series based on occupational/environmental exposures 2
• Consider additional readings at day 6-7 if day 4 results are unexpectedly negative 2

Treatment Based on Extent

Localized Disease

• Mid-to-high potency topical corticosteroids: triamcinolone 0.1% or clobetasol 0.05% 3
• Apply to affected areas until resolution

Extensive Disease (>20% Body Surface Area)

• Systemic corticosteroids required 3
• Provides relief within 12-24 hours
• For severe rhus (poison ivy) dermatitis: taper oral prednisone over 2-3 weeks to prevent rebound dermatitis 3
• Rapid discontinuation causes rebound flares—this is a critical pitfall to avoid

Alternative for Steroid-Unsuitable Cases

• Consider topical tacrolimus when topical steroids are unsuitable or ineffective 2

Chronic Hand Eczema Specific

• Offer alitretinoin for severe chronic hand eczema (strong recommendation) 2
• Consider PUVA therapy as alternative 2
• Consider patient education programs for occupational contact dermatitis 2

Prevention Strategies

• Skin care and skin protection creams help prevent occupational dermatitis 2
• Identify and avoid specific allergens through patch test results
• For occupational cases, investigate workplace products via health and safety data sheets 2
• Look for improvement during weekends/holidays and worsening upon return to work—this pattern strongly suggests occupational etiology 2

Key Clinical Pitfalls

For Urticaria:

• Don't skip antihistamine updosing before adding omalizumab—this is cost-ineffective
• Don't use systemic corticosteroids routinely; reserve for acute intolerable flares only
• Don't stop immunosuppressives before patch testing if unsafe; suboptimal results are better than no testing 2
• Antihistamines don't need to be stopped for patch testing 2

For Contact Dermatitis:

• Don't rely on clinical appearance alone—patch test to confirm diagnosis 2
• Don't use short steroid courses for extensive contact dermatitis—inadequate duration causes rebound 3
• Don't forget to assess quality of life with tools like DLQI and Hand Eczema Severity Index 2
• Don't overlook irritant exposure history, including water and hand-washing frequency 2

Monitoring Disease Activity

• Use Urticaria Control Test (UCT) for urticaria—target score ≥16 for complete control 1
• Use Dermatology Life Quality Index (DLQI) and Hand Eczema Severity Index for contact dermatitis 2
• These objective measures guide treatment escalation and de-escalation decisions